PetMed Express Q4 2024 GAAP EPS $(0.25) Misses $(0.07) Estimate, Sales $66.504M Beat $65.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
PetMed Express (NASDAQ:PETS) reported Q4 2024 GAAP EPS of $(0.25), missing the $(0.07) estimate by 257.14%. Sales were $66.504M, beating the $65.000M estimate by 2.31%. EPS decreased by 2400% from the same period last year, while sales increased by 6.56%.
June 11, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PetMed Express reported a significant miss on EPS for Q4 2024, with a loss of $(0.25) per share compared to the $(0.07) estimate. However, sales were slightly better than expected. The large EPS miss and substantial year-over-year decrease in EPS are likely to negatively impact the stock price in the short term.
The significant miss on EPS and the large year-over-year decrease in EPS are strong negative indicators for investors. Although sales were slightly better than expected, the overall financial performance is likely to lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100